Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2010
11/04/2010US20100278829 Dual inhibition of immunophilin/cyclophilin family members and emmprin immunoglobulin receptor superfamily members
11/04/2010US20100278828 Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
11/04/2010US20100278825 Mammalian Receptor Proteins; Related Reagents and Methods
11/04/2010US20100278824 Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
11/04/2010US20100278818 Antibody specific for the Tn antigen for the treatment of cancer
11/04/2010US20100278811 Vasculostatic agents and methods of use thereof
11/04/2010US20100278810 Methods of Modulating Angiogenesis
11/04/2010US20100278809 Inhibitors of MRP4 for the Treatment of Vascular Disorders
11/04/2010US20100278804 Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders
11/04/2010US20100278803 Alzheimer's Disease Diagnosis Based on Mitogen-Activated Protein Kinase Phosphorylation
11/04/2010US20100278797 Pharmaceutical Composition and Method for Regulating Abnormal Cellular Proliferation
11/04/2010US20100278789 Methods of generating expanded and re-differentiated adult islet beta cells capable of producing insulin
11/04/2010US20100278779 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
11/04/2010US20100278776 Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof
11/04/2010US20100278772 Dna methylation markers and methods of use
11/04/2010US20100278765 Regulation of mammalian keratinous tissue using hexamidine compositions
11/04/2010US20100278764 Cosmetic and/or pharmaceutical composition comprising at least one copolymer comprising at least one ionizable group, and cosmetic treatment process
11/04/2010US20100278760 Cosmetics
11/04/2010US20100278759 Topical Therapeutic Delivery System
11/04/2010US20100278744 Preparation for restenosis prevention
11/04/2010US20100278741 Novel compositions including sphingosine kinase type 1 inhibitors, and processes for using same
11/04/2010US20100278731 Mechanism-Based Targeted Pancreatic Beta Cell Imaging and Therapy
11/04/2010US20100278729 Breast cancer eradication program
11/04/2010US20100278725 Methods and devices for lymphatic targeting
11/04/2010US20100276329 Topical glycopyrrolate formulations
11/04/2010US20100275913 Composition for inhalation
11/04/2010US20100275431 Drug delivery from stents
11/04/2010DE202010007365U1 Applikator zum Abgeben eines Produktes auf Haar An applicator for dispensing a product to hair
11/04/2010DE19549825B4 Zuckerfreie Hartkaramellen Sugar-free hard candies
11/04/2010CA2843996A1 Use of pufas for treating skin inflammation
11/04/2010CA2777479A1 Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
11/04/2010CA2771204A1 Methods and compositions for improving the health of animals
11/04/2010CA2762064A1 Method of reducing intraocular pressure in humans
11/04/2010CA2762009A1 Use of pufas to treat nerve damage
11/04/2010CA2760689A1 Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
11/04/2010CA2760688A1 Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
11/04/2010CA2760687A1 Methods for treating or preventing ophthalmological diseases
11/04/2010CA2760675A1 Serotonin transporter gene and treatment of alcoholism
11/04/2010CA2760630A1 Quaternary ammonium salt compounds
11/04/2010CA2760629A1 Use of pufas for treating skin inflammation
11/04/2010CA2760591A1 Cleanser compositions and methods for using the same
11/04/2010CA2760590A1 Intraocular bioactive agent delivery composition including a molecular partitioning system
11/04/2010CA2760589A1 Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
11/04/2010CA2760562A1 Dual mechanism inhibitors for the treatment of disease
11/04/2010CA2760554A1 Moisturizing antimicrobial composition
11/04/2010CA2760547A1 Schweinfurthins and uses thereof
11/04/2010CA2760541A1 Pyrido[4,3-b] indoles and methods of use
11/04/2010CA2760527A1 Method of treatment of depression
11/04/2010CA2760526A1 Antimicrobial agents
11/04/2010CA2760460A1 Formulations of cannabidiol and methods of using the same
11/04/2010CA2760451A1 Compositions and methods for treating and preventing overactive bladder and conditions associated therewith
11/04/2010CA2760387A1 Thiophene derivative
11/04/2010CA2760357A1 Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
11/04/2010CA2760338A1 Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
11/04/2010CA2760305A1 Ex-vivo treatment of immunological disorders with pkc-theta inhibitors
11/04/2010CA2760292A1 Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
11/04/2010CA2760253A1 Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders
11/04/2010CA2760244A1 Hepcidin binding nucleic acids
11/04/2010CA2760195A1 A pharmaceutical, dermatological, nutritional or cosmetic composition for combating the immunosuppressive action of aggressive agents on the skin
11/04/2010CA2760163A1 Processes and intermediates
11/04/2010CA2760151A1 Pyridinone antagonists of alpha-4 integrins
11/04/2010CA2760138A1 Neuroprotective compounds and their use
11/04/2010CA2760133A1 Treatment of neurodegeneration and neuroinflammation
11/04/2010CA2760128A1 Cannabinoid-containing compositions and methods for their use
11/04/2010CA2760085A1 Oral formulations of bendamustine
11/04/2010CA2760077A1 Substituted imidazoquinoxalines
11/04/2010CA2760073A1 Solid preparation
11/04/2010CA2760052A1 Communication means for communication with and remote activation of downhole tools and devices used in association with wells for production of hydrocarbons
11/04/2010CA2760048A1 Therapeutic agent for motor disorders
11/04/2010CA2760039A1 Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
11/04/2010CA2760031A1 Acetone solvate crystals of trityl olmesartan medoxomil
11/04/2010CA2760017A1 Soluble pharmaceutical forms of n,n'-diaminodiphenyl sulphone for optimum use in the treatment of various diseases
11/04/2010CA2759984A1 Formulation of tocotrienol quinones for the treatment of ophthalmic diseases
11/04/2010CA2759936A1 Oral compositions for skin benefits
11/04/2010CA2759883A1 Treatment or prophylaxis of proliferative conditions
11/04/2010CA2759863A1 Benzamide and naphthamide derivatives inhibiting nuclear factor- kappa (b) - (nf-kb)
11/04/2010CA2759859A1 Carbinol compound having heterocyclic linker
11/04/2010CA2759828A1 Processes for the preparation of rivaroxaban and intermediates thereof
11/04/2010CA2759795A1 Method and composition for treating diabetic ketoacidosis
11/04/2010CA2759791A1 Novel therapeutic treatments using centhaquin
11/04/2010CA2759519A1 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
11/04/2010CA2759494A1 Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
11/04/2010CA2759491A1 Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
11/04/2010CA2759482A1 N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
11/04/2010CA2759476A1 Novel compounds
11/04/2010CA2759471A1 Heteroarylthiomethyl pyridine derivative
11/04/2010CA2759284A1 Stable pharmaceutical composition and methods of using same
11/04/2010CA2759230A1 Therapeutic agents 713
11/04/2010CA2759176A1 Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
11/04/2010CA2759165A1 Concatamers for immunemodulation
11/04/2010CA2759163A1 Method for producing olmesartan medoxomil
11/04/2010CA2759155A1 Antiparasitic agent for fish and method of controlling proliferation of fish parasites
11/04/2010CA2759085A1 Use of allopurinol for the treatment of hand foot skin reaction
11/04/2010CA2759083A1 Imidazole derivatives and their use as modulators of cyclin dependent kinases
11/04/2010CA2759047A1 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
11/04/2010CA2758986A1 Inhibitors of pi3 kinase and/or mtor
11/04/2010CA2758961A1 Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as .beta.-secretase inhibitors
11/04/2010CA2758958A1 Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as .beta.-secretase inhibitors
11/04/2010CA2758928A1 Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
11/04/2010CA2758856A1 Pentamidine combinations for treating cancer
1 ... 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 ... 7860